Ischemic Heart Disease After SARS-CoV-2 Infection: A Cross-Sectional Study
- Authors: Yakhontov D.A.1, Derisheva D.A.1, Khidirova L.D.1, Lukinov V.L.2
-
Affiliations:
- Novosibirsk State Medical University
- Institute of Computational Mathematics and Mathematical Geophysics, Siberian Branch RAS
- Section: Original research
- Submitted: 13.02.2025
- Accepted: 03.06.2025
- Published: 21.09.2025
- URL: https://kazanmedjournal.ru/kazanmedj/article/view/655536
- DOI: https://doi.org/10.17816/KMJ655536
- EDN: https://elibrary.ru/IJZOQU
- ID: 655536
Cite item
Abstract
BACKGROUND: The incidence of newly diagnosed stable angina after a SARS-CoV-2 infection remains high. However, studies on the clinical, functional, and laboratory characteristics of this disease are inadequate. The manifestations of ischemic heart disease (IHD) following SARS-CoV-2 infection require further investigation to elucidate the pathophysiological mechanisms and personalize follow-up care.
AIM: This study aimed to compare the clinical, functional, laboratory, and angiographic characteristics of stable angina in patients diagnosed with IHD following SARS-CoV-2 infection.
METHODS: This cross-sectional study assessed patients’ medical histories, along with clinical, laboratory, and instrumental findings. The study enrolled 428 patients with stable IHD and documented SARS-CoV-2 infection (within 3–18 months of the onset of the disease). Group 1 (n = 195) consisted of patients with newly diagnosed IHD, and group 2 (n = 233) included patients with previously diagnosed IHD, with the infection being documented to have occurred ≥12 weeks prior to study enrollment. IHD was diagnosed through a comprehensive evaluation that included clinical presentation, electrocardiographic analysis, echocardiographic imaging, stress tests, and coronary angiography. Blood chemistry was performed using standardized methods. Statistical analysis was carried out in RStudio. Continuous variables were compared using the Mann–Whitney U test, whereas the comparison of binary and categorical variables was conducted using Fisher’s exact test. The critical significance level was set at p = 0.05.
RESULTS: Group 1 was significantly younger (p = 0.009), had a lower body mass index (p < 0.001), and had a shorter history of hypertension (p < 0.001). These patients exhibited higher prevalence of functional class I angina pectoris (p = 0.006), NYHA class II chronic heart failure (p = 0.005), and lower prevalence of ventricular extrasystole (p = 0.002). Coronary angiography demonstrated that group 1 showed higher prevalence of unchanged coronary arteries (p = 0.003) and hemodynamically insignificant stenoses (p = 0.018), but lower proportion of hemodynamically significant stenoses (p < 0.001). There were no significant differences found in the occurrence of multifocal atherosclerosis (p = 0.132). The treadmill test revealed comparable positive results across both groups (p = 0.479). However, group 1 exhibited a higher frequency of inconclusive results (p = 0.011). The laboratory profile of patients from group 2 showed increased Lp(a) (p = 0.023), triglycerides (p = 0.003), apoB (p = 0.022), NT-proBNP (p = 0.010), D-dimer (p = 0.001), high sensitivity C-reactive protein (p = 0.012), and cystatin C (p = 0.001), as well as higher fasting glucose (p = 0.030), but comparable HbA1c levels (p = 0.750).
CONCLUSION: Patients who develop stable angina following SARS-CoV-2 infection demonstrate a less severe clinical and functional phenotype, less significant coronary atherosclerosis, and more favorable biomarker profile than those with previously diagnosed IHD who had SARS-CoV-2 infection.
About the authors
Davyd A. Yakhontov
Novosibirsk State Medical University
Email: mich99@mail.ru
ORCID iD: 0000-0003-4735-5178
SPIN-code: 5730-7589
MD, Dr. Sci. (Medicine), Professor, Depart. of Pharmacology, Clinical Pharmacology, and Evidence-Based Medicine
Russian Federation, NovosibirskDaria A. Derisheva
Novosibirsk State Medical University
Email: one.d@mail.ru
ORCID iD: 0000-0002-5097-1855
SPIN-code: 9797-7729
Scopus Author ID: 1280588
MD, Cand. Sci. (Medicine), Assistant Professor, Depart. of Pharmacology, Clinical Pharmacology, and Evidence-Based Medicine
Russian Federation, NovosibirskLyudmila D. Khidirova
Novosibirsk State Medical University
Author for correspondence.
Email: h_ludmila73@mail.ru
ORCID iD: 0000-0002-1250-8798
SPIN-code: 7932-6544
Scopus Author ID: 57195757496
ResearcherId: КРК-8739-2024
MD, Dr. Sci. (Medicine), Professor, Depart. of Pharmacology, Clinical Pharmacology, and Evidence-Based Medicine
Russian Federation, NovosibirskVitaly L. Lukinov
Institute of Computational Mathematics and Mathematical Geophysics, Siberian Branch RAS
Email: vitaliy.lukinov@sscc.ru
ORCID iD: 0000-0002-3411-508X
SPIN-code: 3950-3322
Scopus Author ID: 949073
Cand. Sci. (Physics and Mathematics), Leading research associate, Lab. of Numerical Analysis of Stochastic Differential Equations
Russian Federation, NovosibirskReferences
- Soriano JB, Murthy S, Marshall JC, et al; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102–e107. doi: 10.1016/S1473-3099(21)00703-9 EDN: NHYDEH
- O'Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. EClinicalMedicine. 2022;55:101762. doi: 10.1016/j.eclinm.2022.101762 EDN: KUBUIW
- Idris Fadul AA, Osman Mohamed AA, Mohammed Ahmed AAS, et al. Post-coronavirus Disease 2019 (COVID-19) Cardiovascular Manifestations: A Systematic Review of Long-Term Risks and Outcomes. Cureus. 2025;17(4):e83083. doi: 10.7759/cureus.83083.;PMCID
- Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583–590. doi: 10.1038/s41591-022-01689-3 EDN: GXZXAU
- Rajan S, Hunt K, Alwan NA, et al. In the wake of the pandemic: Preparing for Long COVID [Internet]. Copenhagen (Denmark): European Observatory on Health Systems and Policies; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK569598
- Zhang T, Li Z, Mei Q, et al. Cardiovascular outcomes in long COVID-19: a systematic review and meta-analysis. Front Cardiovasc Med. 2025;12:1450470. doi: 10.3389/fcvm.2025.1450470.;PMCID
- Avanoglu Guler A, Tombul N, Aysert Yıldız P, et al. The assessment of serum ACE activity in COVID-19 and its association with clinical features and severity of the disease. Scand J Clin Lab Invest. 2021;81(2):160–165. doi: 10.1080/00365513.2021.1871641 EDN: DOHBWO
- Adu-Amankwaah J, Mprah R, Adekunle AO, et al. The cardiovascular aspect of COVID-19. Ann Med. 2021;53(1):227–236. doi: 10.1080/07853890.2020.1861644 EDN: AKMTRW
- Majure DT, Gruberg L, Saba SG, et al; Northwell Health COVID-19 Research Consortium. Usefulness of elevated troponin to predict death in patients with COVID-19 and myocardial injury. Am J Cardiol. 2021;138:100–106. doi: 10.1016/j.amjcard.2020.09.060.;PMCID EDN: OMCZHY
- Canzano P, Brambilla M, Porro B, Cosentino N. Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients. JACC Basic Transl Sci. 2021;6(3):202–218. doi: 10.1016/j.jacbts.2020.12.009.;PMCID EDN: MJMJOJ
- Writing Committee; Gluckman TJ, Bhave NM, Allen LA, et al. 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;79(17):1717–1756. doi: 10.1016/j.jacc.2022.02.003 EDN: CZLRKH
- Gyöngyösi M, Alcaide P, Asselbergs FW, et al. Long COVID and the cardiovascular system-elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: a joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial and Pericardial Diseases. Cardiovasc Res. 2023;119(2):336–356. doi: 10.1093/cvr/cvac115 EDN: RTNTNO
- Tsampasian V, Bäck M, Bernardi M, et al. Cardiovascular disease as part of Long COVID: a systematic review. Eur J Prev Cardiol. 2025;32(6):485–498. doi: 10.1093/eurjpc/zwae070 EDN: QLXRCO
- Wang W, Wang CY, Wang SI, Wei JC. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. EClinicalMedicine. 2022;53:101619. doi: 10.1016/j.eclinm.2022.101619 EDN: EVNIFG
- Çınar T, Şaylık F, Akbulut T, et al. One-year outcomes of invasively managed acute coronary syndrome patients with COVID-19. Heart Lung. 2022;52:159–164. doi: 10.1016/j.hrtlng.2022.01.012.;PMCID EDN: OZASIV
- Carnevale Schianca GP, Pedrazzoli R, Onolfo S, et al. ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk. Nutr Metab Cardiovasc Dis. 2011;21:406–411. doi: 10.1016/j.numecd.2009.11.002
- Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(3):305–368. doi: 10.1016/j.ejvs.2017.07.018 EDN: YDUSTB
- van den Berg MJ, Bhatt DL, Kappelle LJ, et al. Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria. Eur Heart J. 2017;38(43):3211–3218. doi: 10.1093/eurheartj/ehx102 EDN: VFMEXY
- Grakova EV, Kopieva KV, Teplyakov AT, et al. Clinical use of the new biomarker ST2 in patients with chronic heart failure of ischemic genesis: an exercise test. Cardiovasc Ther Prev. 2019;18(4):12–18. doi: 10.15829/1728-8800-2019-4-12-18 EDN: IVHJZH
- Arutyunov GP, Tarlovskaya EI, Arutyunov AG, et al. Clinical features of post-COVID-19 period. Results of the international register “Dynamic analysis of comorbidities in SARS-CoV-2 survivors (AKTIV SARS-CoV-2)”. Data from 6-month follow-up. Russian Journal of Cardiology. 2021;26(10):4708. doi: 10.15829/1560-4071-2021-4708
- Zhao M, Luo C, He H, Shen B, et al. Decreased low-density lipoprotein cholesterol level indicates poor prognosis of severe and critical COVID-19 patients: a retrospective, single-center study. Front Med. 2021;8:585851. doi: 10.3389/fmed.2021.585851 EDN: DOMYAS
- Kanorskii SG. Post-COVID syndrome: prevalence, organ pathogenesis and routes of correction. A systematic review. Kuban Sci Med Bull. 2021;28(6):90–116. (In Russ.) doi: 10.25207/1608-6228-2021-28-6-90 EDN: KZFQTW
- Gomes SMR, Brito ACS, Manfro WFP, et al. High levels of pro-inflammatory SARS-CoV-2-specific biomarkers revealed by in vitro whole blood cytokine release assay (CRA) in recovered and long-COVID-19 patients. PLoS One. 2023;18(4):e0283983. doi: 10.1371/journal.pone.0283983.;PMCID EDN: EMFKXW
- Elizalde-Díaz JP, Miranda-Narváez CL, Martínez-Lazcano JC, Martínez-Martínez E. The relationship between chronic immune response and neurodegenerative damage in long COVID-19. Front Immunol. 2022;13:1039427. doi: 10.3389/fimmu.2022.1039427 EDN: SILHPD
- Tajmirriahi M, Sami R, Mansurian M, et al. Clinical manifestations and outcomes of COVID-19 in patients with a history of coronary artery disease: a case-control retrospective study. BMC Cardiovasc Disord. 2023;23:241. doi: 10.1186/s12872-023-03256-1 EDN: SEWVGF
Supplementary files
